Bio-Techne Balance Sheet Health
Financial Health criteria checks 5/6
Bio-Techne has a total shareholder equity of $2.0B and total debt of $447.0M, which brings its debt-to-equity ratio to 22.8%. Its total assets and total liabilities are $2.7B and $767.2M respectively. Bio-Techne's EBIT is $257.4M making its interest coverage ratio 24.3. It has cash and short-term investments of $135.7M.
Key information
22.8%
Debt to equity ratio
US$447.00m
Debt
Interest coverage ratio | 24.3x |
Cash | US$135.65m |
Equity | US$1.96b |
Total liabilities | US$767.19m |
Total assets | US$2.73b |
Recent financial health updates
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Recent updates
Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16Bio-Teche announces transition plan for CEO Kummeth
Aug 04Bio-Techne: Resiliency Comes At A Large Premium
Jul 29Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer
Jul 06Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?
Jun 22Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?
Jun 09Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
May 26Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)
May 13Financial Position Analysis
Short Term Liabilities: TECH's short term assets ($590.6M) exceed its short term liabilities ($135.2M).
Long Term Liabilities: TECH's short term assets ($590.6M) do not cover its long term liabilities ($632.0M).
Debt to Equity History and Analysis
Debt Level: TECH's net debt to equity ratio (15.9%) is considered satisfactory.
Reducing Debt: TECH's debt to equity ratio has reduced from 50.2% to 22.8% over the past 5 years.
Debt Coverage: TECH's debt is well covered by operating cash flow (61.8%).
Interest Coverage: TECH's interest payments on its debt are well covered by EBIT (24.3x coverage).